Benjamin Rose
Cleveland, Ohio, 44120, United States
Location status: Recruiting
Location contact
Donna Salaam
CONTACT
Silvia Orsulic-Jeras
PRINCIPAL_INVESTIGATOR
Zoe Fete
CONTACT
NCT Number: NCT07208162
This project aims to culturally adapt the SHARE program for African-Americans in early-moderate stage dementia and their care partner. Upon completion of the adaptation, a pilot randomized-control trial wil be confucted to compare the adaptaed SHARE program versus usual care.
Interested in participating?
Request Info18 year and older
All sexes
Interventional
Not applicable
Cleveland, Ohio, 44120, United States
Location status: Recruiting
Donna Salaam
CONTACT
Silvia Orsulic-Jeras
PRINCIPAL_INVESTIGATOR
Zoe Fete
CONTACT
Aim 1: Review SHARE for Dementia materials with an Advisory Committee (AC; 6-10 African Americans with lived experience and experts) to identify distinct needs of African American care dyads and culturally adapt SHARE using this input. Deliverables: Develop SHARE V1 Culturally tailored V1 SHARE Counselor Manual, V1 SHARE Guide for Families, and V1 SHARE Counselor training Aim 2: Conduct focus groups with African American care dyads (n=2 groups; n=10 dyads total, or until saturation) and community service provider staff (n= 2 groups; n=10, or until saturation) to identify strengths and limitations of the V1 SHARE materials, procedures, and protocols. Deliverables: SHARE for African Americans (Version 2;V2); Culturally tailored V2 SHARE Counselor Manual, V2 SHARE Guide for Families, and V2 SHARE Counselor training Aim 3: Train SHARE counselors (n=20) to implement V2 of SHARE. Aim 4: Examine: a) the acceptability and feasibility and; 2) preliminary efficacy of the culturally adapted V2 of SHARE in a fully powered trial with 120 African American care dyads.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
The intervention group will receive the adapted SHARE Dyadic program, consisting of five, 60-90-minute curriculum-guided sessions with a SHARE Counselor, plus one optional family session.
Control group participants will receive a treatment as usual equivalent: a single, standardized educational and resource session with a packet of information.
Time frame: After each session; within 10 weeks of baseline.
SHARE counselors will report length of each session, and we will determine the number of sessions conducted were within 60-90 minutes - the prescribed treatment protocol.
Time frame: After each session; within 10 weeks of baseline.
SHARE counselors will report the number of sessions attended out of 6 treatment sessions offered.
Time frame: Follow up (T2); within 12 weeks of baseline.
We will assess the number of caregivers and PLWD retained at follow-up
Time frame: After each session; within 10 weeks of baseline.
Caregivers and PLWD will be asked about their satisfaction with SHARE regarding the: 1) experience; 2) counselor; 3) materials; 4) sessions; 5) postintervention relationship functioning.
Time frame: Follow up (T2); within 12-weeks of baseline.
Caregivers and PLWD will be asked to agree or disagree with statements about SHARE Counselor, understanding of choices, knowledge of dementia, connection to care partner.
Time frame: Follow up (T2); within 12 weeks of baseline.
Caregivers and PLWD will be asked to rate their satisfaction with care values and preferences discussions, spacing between sessions, importance of knowledge gained, etc.
Time frame: Follow up (T2); within 12 weeks of baseline.
Caregivers and PLWD will be asked to rate the usefulness of materials and information shared, skill of counselor, commitment to care plan.
Time frame: Follow up (T2); within 12 weeks of baseline.
Caregivers and PLWD will be asked about the appropriateness of time spent in session and number of sessions.
Time frame: Follow up (T2); within 12 weeks of baseline.
Caregivers and PLWD will be asked about the main benefits and drawbacks of SHARE.
Time frame: Follow up (T2); within 12 weeks of baseline.
Caregivers and PLWD will be asked to indicate their goals of participating in SHARE, such as: Dementia education, communication skills, knowledge of resources, building a network of support, etc.
Time frame: Baseline (T1), Follow up (T2); within 12 weeks of baseline.
The Dyadic Relationship Scale consists of 28 items that asks care partners and PLWD how often of the time (15-items), and how often in the past month (13-items), they think a statement applies to their relationship. Responses are (0-3) ranging from "All or nearly all of the time" to "None or almost none of the time". Ranges are a total of 0-84, with higher scores indicating more positive dyadic relationship.
Time frame: Baseline (T1), Follow up (T2); within 12 weeks of baseline.
The Personal and Instrument Activities of Daily Living is a an 18-item measure that asks care partners to rate the PLWD ability to perform daily activities. Responses are (1) Does by self/ Needs no help, (2) Needs reminders/ Needs a little help, (3) Needs help most of the time, and (4) Needs help all the time (unable to do activity). Range is from 18-72, with lower scores indicating less ability of PLWD to perform daily activities independently.
Time frame: Baseline (T1), Follow up (T2); within 12 weeks of baseline.
The Emotional-Intimacy Disruptive Behavior Scale is a an 8-item measure to asks care givers and PLWD to assess the extent care partners with hold or distort symptoms or feelings to protect their care partner. Response options are (1) None of the time, (2) Some of the time, (3) Much of the time, (4) Most or all of the time. Range is from 8-32, with higher scores indicating higher distortions of feelings
Time frame: Baseline (T1), Follow up (T2); within 12 weeks of baseline.
Caregivers and PLWD will be asked six positive/six negative affect indicators.
Time frame: Baseline (T1), Follow up (T2); within 12 weeks of baseline.
Caregivers and PLWD will be asked to respond to a 20-item measure of how often in past week they experience depressive symptoms associated with depression, such as restless sleep, poor appetite, and feeling lonely. Response options range from 0 to 3 for each item (0 = Rarely or None of the Time, 1 = Some or Little of the Time, 2 = Moderately or Much of the time, 3 = Most or Almost All the Time). Scores range from 0 to 60, with high scores indicating greater depressive symptoms.
Time frame: Baseline (T1), Follow up (T2); within 12 weeks of baseline.
Caregivers will be asked open-ended questions.
Time frame: Baseline (T1), Follow up (T2); within 12 weeks of baseline.
Caregivers and PLWD will complete an inventory of enjoyable activities and self-care practices.
Time frame: Baseline (T1), Follow up (T2); within 12 weeks of baseline.
Caregivers and PLWD will respond to a 13-item questionnaire designed to provide a report of the quality of life for the PLWD participant. Response options are from 1 (Poor) - (4) excellent for each item. Range from 13-52, higher scores indicate higher quality of life.
Time frame: After each session; within 10 weeks of baseline.
SHARE counselors will report on dyad's self-care strengths and challenges after sessions 1 & 4 of the treatment intervention.
Time frame: After each session; within 10 weeks of baseline.
Communication skills are 4-items that counselors respond to after each session of the treatment intervention to rate the degree of which care partner and PLWD communicated with the counselor, as well as to rate the quality and balance of amount of talking that occurred during the sessions. Response options range from 1 "Not at all" to 7 "very", with higher scores indicating better communication.
Time frame: Baseline (T1), Follow up (T2); within 12 weeks of baseline.
The Knowledge of Available Service subscale of the Service Availability Measure is a 14-item measure of the PLWD and their care partner's knowledge of different community of mental health services available. Response are (1) yes and (0) no. Range is 0-14, with higher scores indicating higher knowledge of services available.
Time frame: Baseline (T1), Follow up (T2); within 12 weeks of baseline.
The Use of Services subscale of the Service Availability Measure is a 14-item measure of the PLWD and their care partner's use of different community of mental health services available in the past 3 months. Response are (1) yes and (0) no. Range is 0-14, with higher scores indicating higher use of services available.
Time frame: Baseline (T1), Follow up (T2); within 12 weeks of baseline.
The Care Values Scale is a 25-item measure to capture what the PLWD, and their care partners, think are most important to the PLWD's future care. Response options are (1) Not at all important, (2) Somewhat important, (3) Very important. Range is 25-75, with higher scores indicating higher levels of importance to the various domains of care asked.
Time frame: Baseline (T1), Follow up (T2); within 12 weeks of baseline.
The Preferences for Care Tasks Scale is a 19-item measure to capture who the PLWD, and their care partners believe the PLWD, prefers to help them with various care tasks. Response options are (1) the care giver, (2) friends or other family, (3) paid professional help. Range is 19-57, with higher scores indicating higher preferences that care tasks are performed outside of the dyad.
Contact information is provided by the study sponsor or research team.
Silvia Orsulic-Jeras
CONTACT
Zoe Fete
CONTACT
Benjamin Rose Institute on Aging
Other
Adapting the SHARE for Dementia Early-Stage Dyadic Intervention: A Stage I Pilot Study With African-American Families
Acronym: SHARE
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05004688
Alzheimer Disease, Brain Diseases
Charlestown, Massachusetts, United States
View Trial DetailsNCT04913818
Mild Dementia, Moderate Dementia
Hong Kong
View Trial DetailsNCT03282877
Mild Dementia, Moderate Dementia
Derby, Derbyshire, United Kingdom
View Trial DetailsNCT07234357
Behavior, Behavioral Symptoms
Singapore
View Trial Details